Recent Updates
Recently added Catalysts

Anti R-IL2 + Cyclosporine

Phase 3

Renal Transplant | Small molecule | Nephrology |Novartis AG|Last Updated: Jul 8, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment327
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01028092mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal TransplantationPHASE3 COMPLETED 327Mar 1, 2009Jul 1, 2014Jul 8, 201418 France
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
calculated renal function with MDRD equation
12 months
Secondary Endpoints
Acute rejection rate
12 months
Patient and graft survival rate
12 months
Adverse events
12 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ControlACTIVE_COMPARATORanti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
CNI-freeEXPERIMENTALThymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
SwitchEXPERIMENTALanti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
Interventions
NameTypeDescription
Anti R-IL2 + CyclosporineDRUG* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4) * Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0 * cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2 * corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Thymoglobulin + EverolimusDRUG* Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days * Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0 * everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml * corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Anti R-IL2 + Cyclosporine then EverolimusDRUG* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4) * Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0 * cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml * corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Unlock Study Design Details
Eligibility Criteria
Age Range60 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites18

Inclusion Criteria: * Patient who has given written informed consent to participate in the study * First or second single transplantation of a recipient (male or female) older than 60 years old * Donor older than 60 years old * PRA \< 30% Exclusion Criteria: * Living donor * Third transplantation...

Countries:France
Unlock Eligibility Criteria